Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1036

1.

Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH; SHARP Collaborative Group.

Clin J Am Soc Nephrol. 2019 Dec 12. pii: CJN.07320619. doi: 10.2215/CJN.07320619. [Epub ahead of print]

PMID:
31831577
2.

Investigating modifications to participant information materials to improve recruitment into a large randomized trial.

HPS2-THRIVE Collaborative Group, Haynes R, Chen F, Wincott E, Dayanandan R, Lay MJ, Parish S, Bowman L, Landray MJ, Armitage J.

Trials. 2019 Dec 5;20(1):681. doi: 10.1186/s13063-019-3779-4.

3.

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study.

Mafham MM, Bowman LJ, Haynes RJ, Armitage JM.

Diabetologia. 2019 Nov 30. doi: 10.1007/s00125-019-05049-8. [Epub ahead of print] Review.

PMID:
31786655
4.

Removal of Al, Ga, As, V and Mo from alkaline wastewater using pilot-scale constructed wetlands.

Hua T, Haynes RJ, Zhou YF.

Environ Sci Pollut Res Int. 2019 Dec;26(34):35121-35130. doi: 10.1007/s11356-019-06490-3. Epub 2019 Nov 2.

PMID:
31679140
5.

Kidney disease trials for the 21st century: innovations in design and conduct.

Herrington WG, Staplin N, Haynes R.

Nat Rev Nephrol. 2019 Oct 31. doi: 10.1038/s41581-019-0212-x. [Epub ahead of print] Review.

PMID:
31673162
6.

Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.

Oiknine-Djian E, Bar-On S, Laskov I, Lantsberg D, Haynes RK, Panet A, Wolf DG.

Antiviral Res. 2019 Dec;172:104639. doi: 10.1016/j.antiviral.2019.104639. Epub 2019 Oct 22.

PMID:
31654672
7.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

Haynes R, Valdes-Marquez E, Hopewell JC, Chen F, Li J, Parish S, Landray MJ, Armitage J; HPS2-THRIVE Collaborative Group; HPS2-THRIVE Writing Committee members; HPS2-THRIVE Steering Committee members.

Clin Ther. 2019 Sep;41(9):1767-1777. doi: 10.1016/j.clinthera.2019.06.012. Epub 2019 Aug 22.

PMID:
31447131
8.

In Vitro Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against Mycobacterium tuberculosis.

Tanner L, Evans JC, Seldon R, Jordaan A, Warner DF, Haynes RK, Parkinson CJ, Wiesner L.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e01010-19. doi: 10.1128/AAC.01010-19. Print 2019 Nov.

PMID:
31427302
9.

Pathophysiology and management of monoclonal gammopathy of renal significance.

Jain A, Haynes R, Kothari J, Khera A, Soares M, Ramasamy K.

Blood Adv. 2019 Aug 13;3(15):2409-2423. doi: 10.1182/bloodadvances.2019031914. Review.

10.

The Serotonin Brainstem Hypothesis for the Sudden Infant Death Syndrome.

Kinney HC, Haynes RL.

J Neuropathol Exp Neurol. 2019 Sep 1;78(9):765-779. doi: 10.1093/jnen/nlz062.

PMID:
31397480
11.

Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration.

Parkinson CJ, Birrell GW, Chavchich M, Mackenzie D, Haynes RK, de Kock C, Richardson DR, Edstein MD.

J Antimicrob Chemother. 2019 Oct 1;74(10):2965-2973. doi: 10.1093/jac/dkz290.

PMID:
31325302
12.

Anti-Mycobacterial Peroxides: A new class of agents for development against tuberculosis.

van der Westhuyzen CW, Haynes RK, Panayides JL, Wiid I, Parkinson CJ.

Med Chem. 2019 Apr 30. doi: 10.2174/1573406415666190430143535. [Epub ahead of print]

PMID:
31208310
13.

Long term outcomes in monoclonal gammopathy of renal significance.

Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, Rabin N, Kothari J, Alchi B, Haynes R, Winearls C, Roberts I, Ramasamy K.

Br J Haematol. 2019 Sep;186(5):706-716. doi: 10.1111/bjh.15987. Epub 2019 May 29.

PMID:
31141168
14.

Chronic kidney disease, heart failure and neprilysin inhibition.

Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C.

Nephrol Dial Transplant. 2019 Apr 26. pii: gfz058. doi: 10.1093/ndt/gfz058. [Epub ahead of print]

PMID:
31028383
15.

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray MJ, Gray A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int. 2019 Jul;96(1):170-179. doi: 10.1016/j.kint.2019.01.028. Epub 2019 Mar 12.

16.

Outcomes after Epiretinal Membrane Surgery with or Without Internal Limiting Membrane Peeling.

Guber J, Pereni I, Scholl HPN, Guber I, Haynes RJ.

Ophthalmol Ther. 2019 Jun;8(2):297-303. doi: 10.1007/s40123-019-0185-7. Epub 2019 Apr 19.

17.

An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives.

Tanner L, Haynes RK, Wiesner L.

Front Pharmacol. 2019 Feb 18;10:120. doi: 10.3389/fphar.2019.00120. eCollection 2019.

18.

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials.

Offer A, Arnold M, Clarke R, Bennett D, Bowman L, Bulbulia R, Haynes R, Li J, Hopewell JC, Landray M, Armitage J, Collins R, Parish S; Heart Protection Study (HPS), Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), and Treatment of HDL (High-Density Lipoprotein) to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Collaborative Grou.

JAMA Netw Open. 2019 Mar 1;2(3):e190223. doi: 10.1001/jamanetworkopen.2019.0223. Erratum in: JAMA Netw Open. 2019 Mar 1;2(3):e192236.

19.

Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial.

Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, Maingi M, Tjandrawidjaja MC, Heffernan M, Zia MI, Porepa L, Panju M, Thabane L, Graham ID, Haynes RB, Haughton D, Simek KD, Ko DT, Connolly SJ.

JAMA. 2019 Feb 26;321(8):753-761. doi: 10.1001/jama.2019.0710.

20.

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

Herrington WG, Zhu D, Haynes R.

Ann Intern Med. 2019 Feb 19;170(4):JC15. doi: 10.7326/ACPJ201902190-015. No abstract available.

PMID:
30776804
21.

An evidence rating service provided valid correlates of the clinical importance of medical articles and journals.

Haynes RB, Budhram D, Cherian J, Iserman E, Iorio A, Lokker C.

J Clin Epidemiol. 2019 May;109:80-89. doi: 10.1016/j.jclinepi.2019.01.010. Epub 2019 Feb 5.

PMID:
30731116
22.

Mutations in NRXN1 and NRXN2 in a patient with early-onset epileptic encephalopathy and respiratory depression.

Rochtus AM, Trowbridge S, Goldstein RD, Sheidley BR, Prabhu SP, Haynes R, Kinney HC, Poduri AH.

Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1). pii: a003442. doi: 10.1101/mcs.a003442. Print 2019 Feb.

23.

The evaluation of the anti-cancer drug elesclomol that forms a redox-active copper chelate as a potential anti-tubercular drug.

Ngwane AH, Petersen RD, Baker B, Wiid I, Wong HN, Haynes RK.

IUBMB Life. 2019 May;71(5):532-538. doi: 10.1002/iub.2002. Epub 2019 Jan 14.

PMID:
30698324
24.

Estimate of incidence of ROP requiring treatment in extreme preterms and impact on service-7 year review in tertiary unit.

Tavassoli S, Wach R, Haynes R, Markham R, Williams C.

Eye (Lond). 2019 May;33(5):845-849. doi: 10.1038/s41433-018-0330-x. Epub 2019 Jan 16.

PMID:
30651593
25.

Core Competencies in Evidence-Based Practice for Health Professionals: Consensus Statement Based on a Systematic Review and Delphi Survey.

Albarqouni L, Hoffmann T, Straus S, Olsen NR, Young T, Ilic D, Shaneyfelt T, Haynes RB, Guyatt G, Glasziou P.

JAMA Netw Open. 2018 Jun 1;1(2):e180281. doi: 10.1001/jamanetworkopen.2018.0281.

PMID:
30646073
26.

Topical Delivery of Artemisone, Clofazimine and Decoquinate Encapsulated in Vesicles and Their In vitro Efficacy Against Mycobacterium tuberculosis.

van Zyl L, Viljoen JM, Haynes RK, Aucamp M, Ngwane AH, du Plessis J.

AAPS PharmSciTech. 2019 Jan 2;20(1):33. doi: 10.1208/s12249-018-1251-5.

PMID:
30604176
27.

Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal Protection Study-1): Observational Study.

Warner BE, Velardo C, Salvi D, Lafferty K, Crosbie S, Herrington WG, Haynes R.

JMIR Cardio. 2018 Dec 21;2(2). pii: e11332. doi: 10.2196/11332.

28.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

29.

A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes.

Baumgartner PC, Haynes RB, Hersberger KE, Arnet I.

Front Pharmacol. 2018 Nov 20;9:1290. doi: 10.3389/fphar.2018.01290. eCollection 2018.

30.

Growth of Rhodes grass and leaching of ions from seawater neutralized bauxite residues after amendment with gypsum and organic wastes.

Li Y, Haynes RJ, Chandrawana I, Zhou YF.

J Environ Manage. 2019 Feb 1;231:596-604. doi: 10.1016/j.jenvman.2018.10.083. Epub 2018 Oct 31.

PMID:
30388657
31.

Competitive adsorption and desorption of arsenate, vanadate, and molybdate onto the low-cost adsorbent materials alum water treatment sludge and bauxite.

Hua T, Haynes RJ, Zhou YF.

Environ Sci Pollut Res Int. 2018 Dec;25(34):34053-34062. doi: 10.1007/s11356-018-3301-7. Epub 2018 Oct 3.

PMID:
30280345
32.

Synthesis, antimalarial activities and cytotoxicities of amino-artemisinin-1,2-disubstituted ferrocene hybrids.

de Lange C, Coertzen D, Smit FJ, Wentzel JF, Wong HN, Birkholtz LM, Haynes RK, N'Da DD.

Bioorg Med Chem Lett. 2018 Oct 15;28(19):3161-3163. doi: 10.1016/j.bmcl.2018.08.037. Epub 2018 Aug 28.

PMID:
30174153
33.

Corrigendum to 'In vitro activity of artemisone and artemisinin derivatives against extracellular and intracellular Helicobacter pylori' [International Journal of Antimicrobial Agents 48/1 (2016) 101-105].

Sisto F, Scaltrito MM, Masia C, Bonomi A, Coccè V, Marano G, Haynes RK, Miani A, Farronato G, Taramelli D.

Int J Antimicrob Agents. 2018 Oct;52(4):528. doi: 10.1016/j.ijantimicag.2018.08.006. Epub 2018 Aug 30. No abstract available.

PMID:
30172701
34.

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1540-1550. doi: 10.1056/NEJMoa1804989. Epub 2018 Aug 26.

35.

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26.

36.

Formulation of Natural Oil Nano-Emulsions for the Topical Delivery of Clofazimine, Artemisone and Decoquinate.

Burger C, Aucamp M, du Preez J, Haynes RK, Ngwane A, du Plessis J, Gerber M.

Pharm Res. 2018 Aug 7;35(10):186. doi: 10.1007/s11095-018-2471-9.

PMID:
30088097
37.

Diffusion of Proteins across Silica Colloidal Crystals.

Ignacio-de Leon PAA, Eygeris Y, Haynes R, Zharov I.

Langmuir. 2018 Sep 4;34(35):10333-10339. doi: 10.1021/acs.langmuir.8b01261. Epub 2018 Aug 23.

PMID:
30086633
38.

Abnormalities of the Hippocampus in Sudden and Unexpected Death in Early Life.

Kinney HC, Haynes RL, Armstrong DD, Goldstein RD.

In: Duncan JR, Byard RW, editors. SIDS Sudden Infant and Early Childhood Death: The Past, the Present and the Future. Adelaide (AU): University of Adelaide Press; 2018 May. Chapter 29.

39.

Biomarkers of Sudden Infant Death Syndrome (SIDS) Risk and SIDS Death.

Haynes RL.

In: Duncan JR, Byard RW, editors. SIDS Sudden Infant and Early Childhood Death: The Past, the Present and the Future. Adelaide (AU): University of Adelaide Press; 2018 May. Chapter 32.

40.

The management of macular hole retinal detachment and macular retinoschisis in pathological myopia; a UK collaborative study.

Laviers H, Li JO, Grabowska A, Charles SJ, Charteris D, Haynes RJ, Laidlaw DAH, Steel DH, Yorston D, Williamson TH, Zambarakji H; COllaboration of British RetinAl Surgeons (COBRA) study group.

Eye (Lond). 2018 Nov;32(11):1743-1751. doi: 10.1038/s41433-018-0166-4. Epub 2018 Jul 16.

41.

Facile Preparation of N-Glycosylated 10-Piperazinyl Artemisinin Derivatives and Evaluation of Their Antimalarial and Cytotoxic Activities.

Wu Y, Parapini S, Williams ID, Misiano P, Wong HN, Taramelli D, Basilico N, Haynes RK.

Molecules. 2018 Jul 13;23(7). pii: E1713. doi: 10.3390/molecules23071713.

42.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C.

Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.

PMID:
30002098
43.

Properties of seawater neutralized bauxite residues and changes in chemical, physical and microbial properties induced by additions of gypsum and organic matter.

Li Y, Haynes RJ, Chandrawana I, Zhou YF.

J Environ Manage. 2018 Oct 1;223:489-494. doi: 10.1016/j.jenvman.2018.06.070. Epub 2018 Jun 26.

PMID:
29957422
44.

Increased leaching and addition of amendments improve the properties of seawater-neutralized bauxite residue as a growth medium.

Li Y, Haynes RJ, Chandrawana I, Zhou YF.

Environ Sci Pollut Res Int. 2018 Sep;25(25):25476-25485. doi: 10.1007/s11356-018-2564-3. Epub 2018 Jun 27.

PMID:
29951766
45.

A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study.

Del Fiol G, Michelson M, Iorio A, Cotoi C, Haynes RB.

J Med Internet Res. 2018 Jun 25;20(6):e10281. doi: 10.2196/10281.

46.

Cocrystals of the antimalarial drug 11-azaartemisinin with three alkenoic acids of 1:1 or 2:1 stoichiometry.

Nisar M, Wong LWY, Sung HHY, Haynes RK, Williams ID.

Acta Crystallogr C Struct Chem. 2018 Jun 1;74(Pt 6):742-751. doi: 10.1107/S2053229618006320. Epub 2018 May 24.

PMID:
29870011
47.

Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte Stages.

Coertzen D, Reader J, van der Watt M, Nondaba SH, Gibhard L, Wiesner L, Smith P, D'Alessandro S, Taramelli D, Wong HN, du Preez JL, Wu RWK, Birkholtz LM, Haynes RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e02214-17. doi: 10.1128/AAC.02214-17. Print 2018 Aug.

48.

The Evaluation of Metal Co-ordinating Bis-Thiosemicarbazones as Potential Anti-malarial Agents.

Akladios FN, Andrew SD, Boog SJ, de Kock C, Haynes RK, Parkinson CJ.

Med Chem. 2019;15(1):51-58. doi: 10.2174/1573406414666180525132204.

PMID:
29804537
49.

PCSK9 inhibition: ready for prime time in CKD?

Mafham M, Haynes R.

Kidney Int. 2018 Jun;93(6):1267-1269. doi: 10.1016/j.kint.2018.01.030.

PMID:
29792269
50.

Absorptive and Secretory Transport of Selected Artemisinin Derivatives Across Caco-2 Cell Monolayers.

Heyns J, Willers C, Haynes RK, Wong HN, Hamman J, Gouws C.

Curr Drug Deliv. 2018;15(8):1183-1192. doi: 10.2174/1567201815666180518125113.

PMID:
29779481

Supplemental Content

Loading ...
Support Center